VBI Vaccines Inc. Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- VBI Vaccines Inc.'s estimated annual revenue is currently $9.3M per year.
- VBI Vaccines Inc.'s estimated revenue per employee is $155,000
- VBI Vaccines Inc.'s total funding is $211.4M.
- VBI Vaccines Inc. has 60 Employees.
- VBI Vaccines Inc. grew their employee count by 28% last year.
- VBI Vaccines Inc. currently has 1 job openings.
What Is VBI Vaccines Inc.?
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B with the only 3-antigen hepatitis B vaccine, Sci-B-VacÂ®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBIâ€™s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBIâ€™s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.\n\nTo learn more, visit: www.vbivaccines.com\n\nNews and Insights: www.vbivaccines.com/wire/\n\nInvestors: www.vbivaccines.com/investors/\n\nJob Opportunities: www.vbivaccines.com/about/careers/keywords:N/A